The offering involves 1,833,334 ordinary shares paired with an equal number of Series D and Series E warrants. These warrants, exercisable immediately at $3.00, carry staggered expiration dates of one and five years. A.G.P./Alliance Global Partners served as the sole placement agent for the transaction, which is expected to close on or about June 18, 2026, pending customary conditions.

Beyond the immediate capital injection, the company plans to use the proceeds for general working capital. IceCure also signaled a potential shift in its capital structure, reaching an agreement to lower the exercise price of March 2026 warrants from $16.50 to $3.00 per share, contingent on receiving necessary shareholder approval. These moves come as the company continues to market its ProSense system, a liquid-nitrogen-based platform designed as a minimally invasive alternative to traditional surgical tumor removal for breast, kidney, lung, and bone cancers.